Crossmark

Study protocol for a prospective, multicenter, single-arm study investigating the impact of the implementation of standardized hyperkalemia management in chronic kidney disease patients

Crossref DOI link: https://doi.org/10.1186/s12882-026-04801-8

Published Online: 2026-04-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Xie, Yeqing

Li, Yang

Wang, Yimei

Lin, Jing

Nie, Yuxin

Jiang, Wuhua

Song, Nana

Zhao, Shuan

Shen, Ziyan

Li, Qing

Zhang, Xiaoyan

Ding, Xiaoqiang
Funding

Funding for this research was provided by:

AstraZeneca
License Information

Text and Data Mining valid from 2026-04-21

Accepted Manuscript valid from 2026-04-21
More Information

Article History

Received: 17 November 2025

Accepted: 28 January 2026

First Online: 21 April 2026

Declarations

:

: This study was given ethical approval by Ethics Committee of Zhongshan Hospital Fudan University (approval reference B2024-548R), and all patients will be enrolled voluntarily, with the option to withdraw consent at any time during the study. Written informed consent will be obtained from all study participants prior to participation.

: Not applicable.

: Qing Li is employed by Astrazeneca Investment (China) Co. LTD. Other authors declare no competing interests.

Document is current

Any future updates will be listed below